AstraZeneca launches sunvozertinib (ZEGFROVY) in the US after FDA accelerated approval
The U.S. FDA granted accelerated approval to AstraZeneca’s oral EGFR inhibitor sunvozertinib (brand name ZEGFROVY) for adults with advanced NSCLC harboring EGFR exon‑20 insertion mutations who have progressed after platinum‑based chemotherapy. The approval was based on the phase 1/2 WU‑KONG1B trial, which showed a confirmed overall response rate of 46% and a median duration of response of 11.1 months among responders. AstraZeneca has begun commercial distribution of the 200 mg daily dose and has submitted a supplemental new‑drug application for first‑line use, which has received breakthrough‑therapy designation in the United States and China.
Why it matters
AstraZeneca said the launch expands its portfolio in a high‑unmet‑need lung‑cancer segment, creating a new revenue stream once the drug gains market uptake. The supplemental first‑line filing could further broaden the drug’s market if approved, potentially increasing future sales.
Key facts
- 1The FDA granted accelerated approval to sunvozertinib in July 2025 based on the WU‑KONG1B trial. cancernetwork.com
- 2The trial demonstrated a confirmed overall response rate of 46% (95% CI 35%‑57%). cancernetwork.com
- 3Among the 39 responders, the median duration of response was 11.1 months (95% CI 8.2‑not reached). cancernetwork.com
- 4The drug is administered orally at 200 mg once daily with food. targetedonc.com
- 5A supplemental new‑drug application for first‑line use has been submitted to the FDA and China’s CDE, both of which granted breakthrough‑therapy designation. stocktitan.net
- 6AstraZeneca’s senior vice president of US Oncology, Mohit Manrao, said the US launch marks an important step forward for patients with limited treatment options. stocktitan.net
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.